Skip To Main Content
Swathi-Rao Narayanagari on Muck Rack

Swathi-Rao Narayanagari

As seen in: Science Magazine, Cell Press
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Swathi-Rao

Contact Swathi-Rao, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

MDMX acts as a pervasive preleukemic-to-acute myeloid leukemia transition mechanism

|
By Koki Ueda, Rajni Kumari, Emily Schwenger, Justin C. Wheat, Swathi-Rao Narayanagari, Samuel Taylor, Luis A. Carvajal, Kith Pradhan, Boris Bartholdy, Tihomira I. Todorova, Hiroki Goto, Daqian Sun, Jiahao Chen, Jidong Shan, Yinghui Song, Cristina Montagna, Shunbin Xiong, Guillermina Lozano, Andrea Pellagatti, Jacqueline Boultwood, Ulrich Steidl, Oliver Bohorquez
| Cell Press Verified
Main text (Cancer Cell 39, 529–547.e1–e7; April 12, 2021) We, the authors of this article, investigated how MDMX overexpression drives the transition from preleukemia to acute myeloid leukemia across multiple mouse models. Following publication, we were alerted to duplications in the flow cytometry plots in Figure 3E.
Open in Who Shared Issue with article?

Thrombopoietin receptor-independent stimulation of hematopoietic stem cells by eltrombopag

|
By Albert Einstein College, Jiahao Chen, Yun-Ruei Kao, Swathi-Rao Narayanagari
| Science Magazine Verified
Chronic thrombocytopenia can be associated with a variety of conditions, such as bone narrow failure syndromes and immune disorders. It increases the risk of severe bleeding, and therapies such as platelet transfusion or recombinant thrombopoietin are associated with a variety of complications. In contrast, the small-molecule eltrombopag, a thrombopoietin receptor antagonist, has been very effective in treating thrombocytopenia in patients with bone marrow failure. Kao et al.
Open in Who Shared Issue with article?
See all 2 articles